Nigella Sativa Oil Extract and Xenograft Bone Graft in Treatment of Infra-bony Defects

July 31, 2021 updated by: Doaa Ahmed Yousef, Tanta University

Nigella Sativa Oil Extract and Xenograft Bone Graft in Treatment of Infra-bony Defects: a Combined Clinical and Histological Study

The aim of this study will be to evaluate, clinically, and radiographically the effect of Nigella Sativa oil extract Mixed with xenograft versus xenograft alone in the treatment of intra-bony defects in patients with aggressive periodontitis.

Study Overview

Status

Active, not recruiting

Detailed Description

in 10 patients, twenty sites in subjects with, localized aggressive periodontitis, with CAL ≥ 5 will be included in the present study. Sites will be allocated randomly to be surgically treated with, Nigella Sativa oil extract Mixed with xenograft or xenograft alone. At baseline, 3, 6 after surgery, the following clinical parameters (PD, CAL, BOP) and CBCT at baseline and 6 months x-ray will be recorded.

Study Type

Interventional

Enrollment (Anticipated)

10

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gharbiya
      • Tanta, Gharbiya, Egypt, 31511
        • Doaa Ahmed yousef bayoumi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • systemically healthy patients were selected

    • patients who had not received any medications for the previous six months that may interfere with periodontal tissue health or healing.
    • Patients should demonstrate their ability to maintain good oral hygiene

Exclusion Criteria:

  • • Smokers and pregnant patients.

    • Medically compromised patients and systemic conditions precluding periodontal surgery.
    • Subjects who do not comply with oral hygiene measures as evidenced in recall visits.
    • Restoration or caries in the site to be treated or non-vital tooth
    • Restoration or caries in the site to be treated or non-vital tooth

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: test group
10 infrabony defects treated surgically with Nigella Sativa oil extract Mixed with xenograft
Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
Other Names:
  • periodontal surgery
PLACEBO_COMPARATOR: control group
10 infrabony defects treated surgically with xenograft alone
Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
Other Names:
  • periodontal surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
bleeding on probing
Time Frame: 6 months
bleeding on probing will be recorded at baseline, 3, and 6 months at the site to be treated
6 months
clinical attachment level
Time Frame: 6 months
clinical attachment level will be recorded at baseline, 3, and 6 months at the site to be treated
6 months
probing pocket depth
Time Frame: 6 months
probing pocket depth probing pocket depth will be recorded at baseline, 3, and 6 months at the site to be treated
6 months
cone beam x ray measuring bone fill
Time Frame: 6 months
bone fill will be recorded at baseline, and 6 months at the site to be treated
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: doaa bayoumi, PHD, Tanta University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 1, 2020

Primary Completion (ANTICIPATED)

November 1, 2021

Study Completion (ANTICIPATED)

December 1, 2021

Study Registration Dates

First Submitted

January 13, 2021

First Submitted That Met QC Criteria

January 20, 2021

First Posted (ACTUAL)

January 25, 2021

Study Record Updates

Last Update Posted (ACTUAL)

August 3, 2021

Last Update Submitted That Met QC Criteria

July 31, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Localized Aggressive Periodontitis

Clinical Trials on periodontal regenerative surgery

3
Subscribe